|
|
News Breaks
|
September 5, 2010
|
| 15:53 EDT |  | EXEL |
| theflyonthewall.com: | Exelixis reports inducement grants under Nasdaq listing rule 5635(C)(4) | | Exelixis announced that it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees. The restricted stock unit awards vest as to 1/4th of the shares subject to the restricted stock unit award on the first established quarterly vesting date following the one-year anniversary of the employee’s date of hire and thereafter as to 1/16th of the original number of shares subject to the restricted stock unit award on each succeeding November 15th, February 15th, May 15th and August 15th, subject to the new employee’s continued service relationship with Exelixis on each such date. :theflyonthewall.com |
|
|
News For EXEL From The Last 14 Days Check below for free stories on EXEL the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 10, 2012
|
| 06:06 EDT |  | EXEL |
| theflyonthewall.com: | Exelixis 11M share Spot Secondary priced at $5.50 | | The deal size was increased to 11M shares from 10M shares. Goldman acted as lead book running manager for the offering. :theflyonthewall.com |
|
|
February 9, 2012
|
| 16:07 EDT | | EXEL |
|
|
February 8, 2012
|
| 16:17 EDT |  | EXEL |
| theflyonthewall.com: | Exelixis reports Q4 EPS 35c vs. consensus (11c) | | Reports Q4 revenue $93.3M vs. consensus $38.44M. 2010. This increase was primarily due to the recognition of revenue as a result of the acceleration of deferred license revenue and the receipt of a one-time termination fee in connection with the wind-down in December 2011 of a 2009 collaboration with Sanofi for the discovery of inhibitors of Phosphoinositide-3 Kinase. :theflyonthewall.com |
|
|
February 3, 2012
|
| 10:07 EDT |  | EXEL |
| theflyonthewall.com: | Corrected: Gappers reports | | The gapping stocks reports this morning included stocks that traded below $10. All other aspects of the stories remain the same. :theflyonthewall.com |
| | 10:01 EDT | | EXEL |
| | 06:02 EDT | | EXEL |
| theflyonthewall.com: | Exelixis reports preliminary data from Phase 1b cabozanitinib trial | | Exelixis reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma participating in an ongoing phase 1b trial of cabozantinib. As of the January 18, 2012 data cut-off, 25 RCC patients were enrolled with 88% having received prior anti-VEGF therapy, 60% having received prior mTOR inhibitor therapy, and 52% having received ≥1 anti-VEGF and 1 mTOR therapy. Sixty-four percent of patients received ≥ 2 prior anti-cancer agents. Tumor regression was observed in 19 of 21 patients with ≥1 post-baseline assessment. Best overall response was determined per RECIST criteria with 7 of 25 patients showing a confirmed partial response. Importantly, PRs were observed in heavily pretreated patients, including 3 patients with 2-4 prior systemic therapies, and 2 patients with >4 prior systemic therapies. Thirteen additional patients had stable disease as their best response, and only a single patient demonstrated evidence of primary refractoriness to cabozantinib with a best overall response of progressive disease. The rate of disease control at week 16 for all 25 patients is 72%. :theflyonthewall.com |
|
|
January 31, 2012
|
| 06:53 EDT |  | EXEL |
|
|
|
|
|
Subscribe for More Information